Publication Name	World Journal of Meta-Analysis
Manuscript ID	49567
Country	United States

Received	2019-06-18 06:55
Peer-Review Started	2019-06-21 10:26
To Make the First Decision	2019-08-08 09:27
Return for Revision	2019-08-09 00:45
Revised	2019-08-15 14:57
Second Decision	2019-08-16 12:30
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2019-08-20 03:59
Articles in Press	2019-08-20 03:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-08-27 07:41
Publish the Manuscript Online	2019-09-03 07:56

ISSN	2308-3840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Tofacitinib for the treatment of ulcerative colitis: A review of the literature
Manuscript Source	Invited Manuscript
All Author List	Jessica Rosenberg, Joshua M Steinberg and Mark C Mattar
Funding Agency and Grant Number
Corresponding Author	Mark C Mattar, FACG, MD, Academic Research, Associate Professor, Department of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, United States. mark.c.mattar@gunet.georgetown.edu
Key Words	Ulcerative colitis; Tofacitinib; Review; Inflammatory bowel disease; Treatment;
Core Tip	Tofacitinib is a small molecule that is an inhibitor of the Janus kinase signal transduction pathway, and it is the first oral medication approved for chronic use among adults with moderately to severely active ulcerative colitis (UC). Three large phase III trials have shown overall efficacy and safety; however, long-term results and real-world data are lacking in the literature. Our objective is it consolidate the current literature to better understand what is currently known about efficacy, safety, quality of life, and real-world experience with this medication among patients with UC.
Publish Date	2019-09-03 07:56
Citation	Rosenberg J, Steinberg JM, Mattar MC. Tofacitinib for the treatment of ulcerative colitis: A review of the literature. World J Meta-Anal 2019; 7(8): 373-379
URL	https://www.wjgnet.com/2308-3840/full/v7/i8/373.htm
DOI	https://dx.doi.org/10.13105/wjma.v7.i8.373

Full Article (PDF)	WJMA-7-373.pdf
Full Article (Word)	WJMA-7-373.docx
Manuscript File	49567-Review.docx
Answering Reviewers	49567-Answering reviewers.pdf
Audio Core Tip	49567-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	49567-Conflict-of-interest statement.pdf
Copyright License Agreement	49567-Copyright license agreement.pdf
Peer-review Report	49567-Peer-review(s).pdf
Scientific Misconduct Check	49567-Scientific misconduct check.pdf
Scientific Editor Work List	49567-Scientific editor work list.pdf
CrossCheck Report	49567-CrossCheck Report.pdf